SCHEMBL208454

SCHEMBL208454

CN(C)C1(Cc2cccc(Cl)c2)CCC(NC(=O)CCC(=O)NCCc2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KMT2A Q03164 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
HPGD P15428 3/20 0.50
RXFP1 Q9HBX9 1/20 0.49
MEN1 O00255 1/20 0.48
PLAAT3 P53816 2/20 0.46
PLAAT5 Q96KN8 2/20 0.46
PLAAT2 Q9NWW9 2/20 0.46
PLAAT4 Q9UL19 2/20 0.46
SIGMAR1 Q99720 1/20 0.45
EPHX2 P34913 1/20 0.45
THRB P10828 1/20 0.45
MAPT P10636 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
GLA P06280 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
OPRM1 P35372 1/20 0.43
OPRL1 P41146 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205735 0.96 ALDH1A1 (0.55) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
SCHEMBL206988 0.95 ALDH1A1 (0.51) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
Hydrochloric Acid SCHEMBL206061 0.94 ALDH1A1 (0.50) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
SCHEMBL207910 0.94 OPRM1 (0.50) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
SCHEMBL206651 0.93 EPHX2 (0.46) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
SCHEMBL206288 0.92 ALDH1A1 (0.50) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
SCHEMBL208794 0.91 ALDH1A1 (0.44) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
SCHEMBL206160 0.91 ALDH1A1 (0.49) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1
SCHEMBL206736 0.90 HPGD (0.48) ALDH1A1KMT2ASMN1; SMN2HPGDMEN1
SCHEMBL207325 0.89 NPC1 (0.49) ALDH1A1KMT2ASMN1; SMN2HPGDRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
WO-2009155362-A1 SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2009-12-23 WO disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD ALDH1A1 158/4885KMT2A 3604/4885SMN1; SMN2 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.